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The prevalence of atrial fibrillation (AF) in the United States was estimated to be 3.03 million persons in 2005 1 and is strongly associated with increasing age. 1 Because AF is a major risk factor for cardioembolic stroke, 2, 3 there is an urgent need to develop strategies for identification of AF and prevention of cardioembolic stroke at all ages.
The ischemic stroke rate among patients with AF averages 5% yearly 2 but varies greatly depending on individual clinical characteristics such as age, sex, race/ethnicity, and associated stroke risk factors. History of stroke or TIA identifies those patients with a high stroke risk, averaging 10% yearly. 3 This evidence-based guideline updates a 1998 American Academy of Neurology (AAN) practice parameter on stroke prevention in nonvalvular atrial fibrillation (NVAF). 4 The complete guideline on which this summary is based is available as an online data supplement on the Neurology ® Web site at www. neurology.org. This updated guideline reviews the evidence published since 1998 with regard to the detection of NVAF in patients with stroke and new therapies for the prevention of stroke in patients with NVAF, with a focus on 2 questions: 1) For patients with cryptogenic stroke, how often do various technologies identify previously undetected NVAF? 2) For patients with NVAF, which therapies that include antithrombotic medication, as compared with no therapy or with another therapy, reduce stroke risk and severity with the least risk of hemorrhage?
DESCRIPTION OF THE ANALYTIC PROCESS This guideline was developed in accordance with the processes described in the AAN guideline development process manuals (2004, 2011) . 5, 6 The panel searched MEDLINE, EMBASE, Cochrane, and Web of Science using appropriate search terms to locate relevant articles published between 1998 and March 2013. The search was restricted to peer-reviewed articles on human subjects written in English.
The panel synthesized the evidence and developed conclusions using a modified form of the Grading of Recommendations Assessment, Development and Evaluation process. 7 Evidence synthesis tables are available in appendix e-6 of the complete guideline.
The panel formulated practice recommendations on the basis of the strength of evidence systematically reviewed and other factors, including axiomatic principles of care, the magnitude of anticipated health benefits relative to harms, financial burden, availability of interventions, and patient preferences. The panel assigned levels of obligation (A, B, C, U) to the recommendations using a modified Delphi process.
ANALYSIS OF EVIDENCE For patients with cryptogenic stroke, how often do various technologies identify previously undetected NVAF? Two Class II 8, 9 and 15 Class III [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] studies were identified that address this question. Figure 1 lists these studies and the associated monitoring techniques and durations involved. Studies were downgraded 1 level if they failed to provide data on a cryptogenic stroke cohort, because some of the patients in noncryptogenic cohorts had known NVAF.
The most common technique used to identify NVAF in these studies was Holter monitoring, [12] [13] [14] [15] [16] [17] [18] [19] followed by serial EKG, 8, 16, 17, 19 event loop recorders, 11, 19, 20, 22 inpatient continuous EKG telemetry, 10 outpatient transtelephonic EKG monitoring, 21 and mobile cardiac outpatient telemetry. 9, 23, 24 Several studies described a stepwise approach for NVAF screening that used serial EKGs and Holter monitoring. 16, 17, 19 Monitoring duration varied from 24 hours [13] [14] [15] 18 to 30 days. 8, 21, 22 The proportion of patients identified with NVAF (figure 1) ranged from 0% 15 to 23%. 9 Some of these estimates of NVAF incidence include very brief (e.g., ,30 seconds) episodes, and the future risk of cardioembolic stroke in this setting is uncertain. The average detection rate of all studies was 10.7% (95% confidence interval [CI] 7.9%-14.3%) (weighted average calculated using a random effects model).
A meta-regression of studies using continuous monitoring techniques [8] [9] [10] [11] [12] [13] [14] [15] [18] [19] [20] [22] [23] [24] identified a significant increase in NVAF detection with longer monitoring duration (p , 0.0000).
Conclusions. In patients with recent cryptogenic stroke, cardiac rhythm monitoring probably detects previously unidentified NVAF at a rate ranging from 0% to 23% (weighted average of 10 [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] ). The detection rate is probably related to the duration of monitoring. 25, 26 ).
Antithrombotics compared with warfarin or its derivatives.
Our search strategy identified 6 randomized studies [27] [28] [29] [30] [31] [32] (5 Class I studies, 27-31 1 Class II study 32 ) comparing various antithrombotic regimens with warfarin or its derivatives in patients with NVAF. All studies employed masked or adjudicated outcome assessment. Antithrombotic regimens studied were dabigatran, 27 rivaroxaban, 28 apixaban, 29 fluindione plus aspirin, 32 clopidogrel plus aspirin, 30 and triflusal plus acenocoumarol. 31 Dabigatran is a direct thrombin inhibitor. Rivaroxaban and apixaban are factor Xa inhibitors. Dabigatran, rivaroxaban, and apixaban are administered in fixed doses and do not require regular blood coagulation monitoring. Antithrombotic reversal agents for these drugs are unavailable.
Triflusal is an antiplatelet drug structurally related to aspirin that is used in Europe, Latin America, and Southeast Asia (see appendix e-9 of the complete guideline for the relevant countries). 33, 34 Acenocoumarol, a coumarin derivative, is used mostly in European countries. Fluindione is a vitamin K antagonist used in France. Figure 2 summarizes the effects (relative risk reductions [RRRs]) of these antithrombotic regimens as compared with dose-adjusted warfarin for the outcomes of stroke or systemic embolism, ischemic stroke, major bleeding, intracranial bleeding, and gastrointestinal (GI) bleeding from the Class I studies. The Class II study of fluindione plus aspirin 32 demonstrated that the risk of hemorrhagic complications was increased in the dose-adjusted vitamin K antagonist plus aspirin group as compared with the vitamin K antagonist alone group (risk difference 14.6% [95% CI 5.5%-24.8%]). The study lacked the power to detect important differences in the risk of thromboembolic events.
Conclusions. In patients with NVAF, dabigatran administration is probably more effective for reducing the risk of stroke or systemic embolism (150 mg twice daily, relative risk [RR] 0.66; RRR 34%) than is warfarin administration. Hemorrhage risks were similar overall between dabigatran 150 mg administration twice daily and warfarin administration (INR 2.0-3.0), but intracranial hemorrhage was less frequent with administration of dabigatran 150 mg twice daily (dabigatran vs warfarin, RR 0.40 [95% CI 0.27%-0.60%]) (1 Class I study 27 ). Dabigatran 150 mg bid was associated with a higher rate of GI bleeding (1.51%/y vs 1.02%/y).
In patients with NVAF at high risk of cerebral or systemic embolism, rivaroxaban is probably as effective as warfarin for the prevention of cerebral and systemic embolism, without difference in the risks of major bleeding episodes overall except GI bleeding. However, rivaroxaban is associated with a lesser frequency of intracranial hemorrhage and fatal bleeding as compared with warfarin (RRR 22% [95% CI 5.5%-35.3%]) (single Class I study 28 ). Apixaban 5 mg twice daily is likely more effective than warfarin in patients with NVAF at moderate risk of embolism (RRR 20.3% [95% CI 4.8%-33.3%]). The superiority of apixaban is related to decreased risk of bleeding (including intracranial bleeding) and reduced mortality (1 Class I study 29 ), whereas its effect on reduction of risk of cerebral and systemic embolism is not superior to that of warfarin. 29 In patients who have NVAF and are at risk of stroke, oral anticoagulation therapy is likely more effective than clopidogrel plus aspirin for stroke prevention (RR stroke 1.72). Intracranial bleeding is more common with oral anticoagulation therapy than with clopidogrel plus aspirin (single Class I study 30 ). In patients who have NVAF and are at moderate stroke risk, treatment with triflusal plus acenocoumarol and moderate-intensity anticoagulation (INR target 1.25-2.0) is likely more effective than treatment with acenocoumarol alone and conventional-intensity anticoagulation (INR target 2.0-3.0) for reducing stroke risk (RRR 61%, vascular death, TIA, nonfatal stroke, systemic embolism plus severe bleeding) (single Class I study, 31 smaller than recent studies with new oral anticoagulants).
In patients with NVAF, the combination of lowdose aspirin and dose-adjusted vitamin K antagonist therapy probably increases the risk of hemorrhagic complications (1 Class II study 32 ). There is insufficient evidence to determine whether the combination of aspirin and vitamin K antagonist therapy decreases the risk of ischemic stroke or other thromboembolic events.
Antithrombotics compared with aspirin. Our search strategy identified 2 randomized Class I studies 35, 36 comparing different antithrombotic regimens with aspirin in patients with NVAF. Antithrombotic regimens studied were apixaban and clopidogrel plus aspirin.
Conclusions. Based on 1 Class I study, 35 apixaban 5 mg twice daily is likely more effective than aspirin for decreasing risk of stroke or systemic embolism in patients with NVAF who have a moderate risk of embolism and are not candidates for warfarin treatment (RRR 55.1% [95% CI 37.8%-67.6%]). Bleeding risks are similar for both treatment forms.
In patients with NVAF for whom vitamin K antagonist therapy is unsuitable, the combination of clopidogrel and aspirin (as compared with aspirin alone) reduces the risk of major vascular events, especially stroke (RR 0.72 relative to aspirin), but increases the risk of major hemorrhage (RR 1.57 relative to aspirin), including intracranial bleeding (RR 1.87 [95% CI 1.19-2.94]) (1 Class I study 36 ).
Anticoagulants in special populations. One Class I study 37 randomized patients aged $75 years with NVAF to warfarin (INR 2.0-3.0) or aspirin 75 mg/d. The RRR for disabling stroke (including intracranial hemorrhage) or systemic embolism favoring warfarin was 52% (95% CI 20%-72%). Extracranial hemorrhage rates were similar in the 2 treatment groups.
In a Class II study, 38 Among patients with chronic kidney disease (CKD) participating in the Stroke Prevention in Atrial Fibrillation III (Class I) trials, 39 adjusted-dose warfarin (INR target 2.0-3.0) reduced ischemic stroke/systemic embolism in patients with CKD and a high risk of stroke (RRR 76% [95% CI 42%-90%]) as compared with aspirin or low-dose warfarin, with no difference in major hemorrhage rates.
For patients with stage 3 CKD, 40 apixaban as compared with aspirin significantly reduced stroke and systemic embolism event rates (HR 0.32 [95% CI 0.18-0.55], p , 0.001) without an increase in major bleeding (absolute rate apixaban 2.5% vs aspirin 2.2%) (1 Class I study).
Conclusion. The benefit of anticoagulation likely extends to elderly patients (1 Class I study 37 ) and patients with CKD (2 Class I studies 39, 40 ). Bleeding risk increases in all patients with CKD taking warfarin. Practice recommendations.
A1. Clinicians might obtain outpatient cardiac rhythm studies in patients with cryptogenic stroke without known NVAF, to identify patients with occult NVAF (Level C). A2. Clinicians might obtain cardiac rhythm studies for prolonged periods (e.g., for 1 or more weeks) instead of shorter periods (e.g., 24 hours) in patients with cryptogenic stroke without known NVAF, to increase the yield of identification of patients with occult NVAF (Level C).
Selection of patients for antithrombotic therapy. Clinical context. Within the NVAF population, the absolute risk of ischemic stroke varies widely on the basis of the presence of other stroke risk factors. 4 The absolute stroke risk is highest among patients with NVAF and a history of stroke and TIA (aggregated absolute risk about 10%/y). 4 Although multiple risk stratification tools are available for estimating the absolute stroke risk of patients with NVAF, the absolute stroke risks estimated by these tools vary widely. Because it is difficult to determine with precision the absolute stroke risk in patients with NVAF, determining when the benefit from reduced stroke risk outweighs the harm of increased bleeding is likewise difficult. In these circumstances, patient preferences and physician judgment become especially important.
Practice recommendations.
B1. Clinicians should inform patients with NVAF
that these patients have an increased stroke risk and that this risk can potentially be reduced by antithrombotic use. Patients should also be informed that antithrombotic use increases their risk of major bleeding (Level B).
B2. Clinicians should counsel all patients with NVAF that the decision to use antithrombotics must be made only after the potential benefit from the stroke risk reduction has been weighed against the potential harm from the increased risk of major bleeding. Clinicians should also emphasize the important role of judgment and preferences in this decision (Level B). B3. Clinicians should routinely offer anticoagulation to patients with NVAF and a history of TIA or stroke, to reduce these patients' subsequent risk of ischemic stroke (Level B). B4. Clinicians might not offer anticoagulation to patients with NVAF who lack additional risk factors ("lone" NVAF patients). Clinicians might reasonably offer antithrombotic therapy with aspirin to such patients or might not offer antithrombotic therapy at all (Level C). B5. To inform their judgments as to which patients with NVAF might benefit more from anticoagulation, clinicians should use a risk stratification scheme to help identify patients with NVAF who are at higher risk for stroke or at no clinically significant risk. However, clinicians should not rigidly interpret anticoagulation thresholds suggested by these tools as being definitive indicators of which patients require anticoagulation (Level B).
Selection of a specific oral anticoagulant. Clinical context.
Our review indicates that several anticoagulant medications decrease the risk of ischemic stroke in patients with NVAF. In clinical trials, the new oral anticoagulants are noninferior or superior to warfarin for reducing stroke, and in most patients the reduction in ischemic stroke risk outweighs the risk of bleeding complications. Patients already taking warfarin. Duration of warfarin treatment and time in optimal INR therapeutic range (2.0-3.0) are predictors of favorable efficacy and safety. 25 Practice recommendation.
C2. Clinicians might recommend that patients taking
warfarin whose condition is well-controlled continue warfarin treatment rather than switch to treatment with a new oral anticoagulant (Level C). C3. Clinicians should administer dabigatran, rivaroxaban, or apixaban to patients who have NVAF requiring anticoagulant medication and are at higher risk of intracranial bleeding (Level B).
GI bleeding risk. In patients with NVAF, GI bleeding was greater with dabigatran 150 mg twice daily as compared with warfarin (1.51%/y vs warfarin 1.02%/y). Bleeding from GI sites occurred more frequently in the rivaroxaban group than in the warfarin group, as did bleeding that led to a drop in the hemoglobin level or required transfusion (decrease in hemoglobin $2 g/dL, 2.8%/y in rivaroxaban group vs 2.3%/y in warfarin group). GI bleeding was nonsignificantly lesser with apixaban (0.76%/y) relative to that with warfarin (0.86%/y).
Practice recommendation.
C4. Clinicians might offer apixaban to patients with NVAF and GI bleeding risk who require anticoagulant medication (Level C).
Other factors affecting administration of new oral anticoagulants. INR monitoring is not required for dabigatran, rivaroxaban, and apixaban for maintaining anticoagulation within the therapeutic window. Liberation from frequent periodic INR testing may be attractive to patients unwilling or unable to submit to frequent periodic testing.
C5. Clinicians should offer dabigatran, rivaroxaban, or apixaban to patients unwilling or unable to submit to frequent periodic testing of INR levels (Level B).
Patients with NVAF who are at risk for stroke and unsuitable candidates for warfarin treatment are candidates for alternative treatment with aspirin, but the results are poor in view of the substantially lower level of protection conferred by aspirin (22% RRR) relative to that by warfarin (RRR 68% Apixaban was compared specifically with aspirin in subjects who were unsuitable for or unwilling to receive warfarin for embolism prevention, and apixaban was shown to be superior to aspirin in preventing cerebral and systemic embolism (apixaban group, 1.6%/y vs aspirin group, 3.7%/y), with equal risk of major bleeding, including intracranial hemorrhage.
C6. Clinicians should offer apixaban to patients unsuitable for being treated, or unwilling to be treated, with warfarin (Level B). C7. Where apixaban is unavailable, clinicians might offer dabigatran or rivaroxaban (Level C). C8. Where oral anticoagulants are unavailable, clinicians might offer a combination of aspirin and clopidogrel (Level C).
In patients with NVAF and moderate stroke risk, treatment with triflusal 600 mg/d plus moderateintensity anticoagulation (INR 1.25-2.0) with acenocoumarol is likely more effective than treatment with acenocoumarol alone (INR 2.0-3.0) for reducing all stroke risk (RRR, 61% in vascular death, TIA, and nonfatal stroke or systemic embolism). The reduction in vascular risk is also related to a reduction in severe bleeding, a biologic phenomenon consistent with that found in previous studies. 33, 34 Practice recommendation.
C9. Where triflusal is available and patients are unable or unwilling to take new oral anticoagulants (mostly in developing countries), clinicians should offer acenocoumarol (target INR 1.25-2.0) and triflusal to patients with NVAF who are at moderate stroke risk and higher bleeding risk (Level B).
Special populations. Clinical context. Some clinicians are reluctant to use anticoagulants to treat elderly patients with NVAF because of perceived high risk of bleeding. e8 However, anticoagulation with warfarin is superior to that with aspirin for reducing the risk of ischemic stroke in patients $75 years with NVAF, whereas rates of major bleeding are comparable. 37 In one important subgroup, elderly patients who have frequent falls or advanced dementia, data are insufficient to determine whether anticoagulants are safe or effective. One study that used a decision analysis model estimated that an elderly patient would need to fall 295 times in 1 year to offset the stroke reduction benefits with warfarin. 
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